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Background: The study of regulatory B cells (Bregs) in systemic lupus 
erythematosus (SLE) has been in full swing in recent years, but the number 
and function of Bregs in SLE patients have also present quite contradictory 
results. Therefore, we conducted a meta-analysis to verify the changes in 
Bregs in active SLE. Methods: We identified studies reporting the pro-
portions of Bregs in SLE patients by searching Pubmed, Embase, Web of 
Science, Cochrane and CNKI. Due to the degree of heterogeneity is very 
high, we used a random effects model to assess the mean differences in 
percentages of Bregs between active SLE and controls. Then, sensitivity 
analysis and subgroup analysis were performed to verify potential sources 
of heterogeneity. Results: Seven eligible articles involving 301 active SLE 
patients and 218 controls were included in the meta-analysis. The pooled 
percentages of Bregs were found no significant difference between active 
SLE patients and healthy controls [0.259, (−1.150, 1.668), p = 0.719], with 
great heterogeneity ( I2 = 97.5%) . The result of sensitivity analysis showed 
that exclusion of any single study or single article did not materially re-
solve the heterogeneity, but after excluding the article conducted by Cai 
X and his colleagues, the percentages of Bregs were significantly higher 
in active SLE than those in controls [1.394, (0.114,2.675), p = 0.033]. The 
results of subgroup analysis revealed that when the disease activity was 
judged by SLEDAI score ≥ 5, the percentages of Bregs were significantly 
lower in the SLE groups than in the control groups[-1.99,(-3.241,-0.739), 
p = 0.002], but when the threshold of SLEDAI score ≥ 6 chosen for active 
SLE, the percentages of Bregs were significantly increased in the SLE 
groups[2.546,(1.333,3.759), p < 0.001]. Meanwhile, other subgroup analy-
sis based on the different phenotypes of Bregs, diagnostic criteria, enrolled 
research countries, treatment status, and organ involvement did not differ in 
proportion of Bregs between SLE patients and controls. Conclusions: The 
study implies that Bregs may play a role in the pathogenesis of active SLE, 
and the thresholds of SLEDAI score to distinguish between active and inac-
tive SLE patients are important factors affecting the percentages of Bregs.
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1. Introduction
Systemic lupus erythematosus (SLE) is an autoim-mune connective tissue disease involving multiple organs, which is common in young women. There 
are excessive activation of various immune cells and se-
cretion of autoantibodies, and antigen-antibody complexes 
formed by binding of autoantibodies to antigens are de-
posited on skin, joints and other positions to cause tissue 
damage and diseases. In recent years, the role of regula-
tory B cells (Bregs) in SLE has been attracted widespread 
attention. This type cells interact with CD4+ T cells by 
secreting cytokines , directly contacting among cells, and 
involving in immune responses, which are closely related 
to the pathogenesis and disease activity of SLE.
Bregs are a subgroup of B cells, which play a role 
in immune regulatory mainly through the secretion of 
regulatory cytokines such as interleukin(IL)-10 and 
transforming growth factor (TGF) –β and expression of 
inhibitory antibodies that inhibit pathogenic T cells and 
autoreactive B cells [1]. The hypothesis of regulatory B 
cells can suppress the immune system was first proposed 
in the 1970s, and they are capable of producing inhibito-
ry antibodies to maintain this inhibitory function [2]. The 
regulatory function of B cells in autoimmune diseases was 
first discovered by Janeway et al. in experimental autoim-
mune encephalomyelitis (EAE) in murine. They found B 
cells are not required for EAE induction, but may play an 
immunomodulatory role in EAE from acute to complete 
recovery [3]. With the further research on Bregs, it has 
been found that there are many subtypes of Bregs, such 
as marginal B cells, IL-10-producing Bregs (Br1 or B10), 
TGF-β-producing Bregs (Br3), Foxp3-expressing Bregs 
and other Bregs that have cytotoxic effects [4].
Human Bregs are categorized mainly as either transi-
tional (CD19+CD24highCD38high) or memory (CD24high-
CD27+) [5,6]. The production of proinflammatory factors by 
CD4+T cells can be inhibited by CD19+CD24highCD38high 
Bregs, relying on IL-10, CD80 and CD86, but not TGF-β 
[6]. CD19+CD25highCD86highCD1dhigh Bregs produce IL-
10 and TGF-β that inhibit CD4+T cells proliferation and 
enhance expression of FoxP3 and T lyphocyte antigen 4 in 
regulatory T cells [7]. CD24highCD27+ Bregs also regulate 
the production of TNF-α by producing IL-10 [6]. Therefore, 
human Bregs are not a single phenotype, but regardless of 
phenotype, most of their regulatory function depends on IL-
10. Although there are few studies on human regulatory B 
cells, evidence suggested that they may become targets for 
the treatment of human immune diseases in the future.
Despite these evidences, we still lack confidence in the 
beneficial effects that therapeutic Bregs may have on SLE 
patients. The use of Breg-based therapies should be based 
on changes in the number of Bregs and/or impaired regu-
latory function associated with the pathogenesis of SLE. 
However, the results of studies on the number of Bregs in 
active SLE patients and normal healthy people are quite 
contradictory; the frequency of Bregs in SLE patients is 
reduced or increased [8-14]. Importantly, the role of Bregs in 
SLE is also controversial. It is conceivable that quantifying 
Breg’s strategy is crucial to draw conclusions about Breg 
subtypes. In addition, differences in patients recruitment 
(research country, diagnostic criteria, treatment status, dis-
ease activity, organ involvement) may also be the cause of 
significant differences in the literature. However, to the best 
of our knowledge, no source of these inconsistent results 
has been studied. It is still unclear that the quantitative and 
qualitative changes about Bregs in SLE, but immunother-
apy based on Bregs shows promising therapeutic power, 
thus we performed this meta-analysis to obtain more infor-
mation about Bregs in SLE patients, explore the reasons for 
inconsistent sources of results, and gain a more detailed un-
derstanding of the role of Bregs in the pathogenesis of SLE.
2. Methods
2.1 Search Strategy
The literature search was conducted in Pubmed, Em-
base, Web of Science, Cochrane and CNKI using the 
MeSH terms “regulatory B cell” and “systemic lupus er-
ythematosus” and their combination. We searched for rel-
evant studies that were updated to October 20, 2019. All 
potentially eligible articles were also considered except 
for murine experiments, reviews and conference abstract 
superseded by publication. There were no limits on geo-
graphical location and ethnicity.
2.2 Eligibility Criteria
Studies that fulfilled the following criteria were included: 
(1) evaluating the levels of Bregs in SLE patients and 
controls; (2)the levels of Bregs were presented as ratio of 
Bregs to total lymphocytes(%); (3) available as a full text 
article; (4) providing mean (standard deviation/ standard 
error) or median (range/ interquartile range); (5) case-con-
trol study. Reviews, studies about murine experiments, 
conference abstracts that were not published as full-length 
articles were not included.
2.3 Data Extraction
Two independent researchers selected and recorded eligi-
ble articles. The other researchers were consulted to reach 
a consensus when any divergence occurred. The following 
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information was extracted from the studies: first author’s 
name, publication time, regions where the authors per-
formed studies, diagnostic criteria, Breg definition, treat-
ment status, threshold of SLEDAI chosen to define active 
SLE, the number of patients and controls, the frequency 
of Bregs(%). When the medians and ranges (or interquar-
tile ranges) were provided in studies instead of means and 
standard deviations, we calculated the means and standard 
deviations by estimation methods [15]. The quality of in-
cluded studies was evaluated by the Newcastle-Ottawa 
Quality Assessment Scale (NOS).
2.4 Statistical Analysis
We used the I2-statistic to explore the heterogeneity 
among studies. The I2 values of 25, 50, and 75%, re-
spectively, were used as evidence of low, medium, and 
high heterogeneity. When the pooled results were in high 
heterogeneity, a random effects model was used, and a 
fixed-effects model was used in the case of low hetero-
geneity or no heterogeneity. We performed other analysis 
when heterogeneity was high, including subgroup analysis 
and publication bias to explore heterogeneity. We explored 
the heterogeneity of researches by drawing forest plots to 
visualize the results more intuitively. By examining funnel 
plot asymmetry using the Begger and Egger tests (p≥0.05), 
we assessed the publication bias. We also performed a 
sensitivity analysis to test the robustness of the original 
results. All statistical analysis were performed using Stata 
software (ver.15.0). This meta-analysis was conducted ac-
cording to the PRISMA guidelines.
3. Results
3.1 Literature Search
We searched the database for 1779 articles that might be 
eligible. The flow chart about the screening process of lit-
eratures is shown in Figure 1. We excluded 1677 articles 
by screening headlines and abstracts. Then 16 duplicated 
articles were excluded, 15 articles were not case-control 
trials, 15 articles were not for SLE patients, 14 articles 
were conference abstract superseded by publications, 17 
articles did not provide relevant data, and 18 articles could 
not obtain full-text information. Therefore, this meta-anal-
ysis included a total of seven articles [8-14]. 
3.2 Study Characteristics
All main characteristics of the included studies are pre-
sented in Table 1. These studies were published between 
2014 and 2019. The analysis included 301 active SLE 
patients and 218 controls from seven eligible articles. Of 
these articles, five were conducted in China [8,10,12-14], one 
in Israel [11] and one in Germany [9]. The diagnose criteria 
of SLE varied across studies. All controls were healthy 
people without any autoimmune disease. We regarded all 
studies as case-control studies and scored them using the 
NOS, and all studies had a scored of 5-6.
Table 1. Characteristics of studies included in the meta-analysis
References Region Diagnosis criteria
Treatment 
status
Threshold of 
SLEDAI for 
active SLE
Breg definition
Case Control Bregs in case Bregs in control NOS 
score(n) (n) (mean±SD,%) (mean±SD,%)
Cai X et al. China 1997 Not report ≥5 IL-10+CD19+ 38 20 1.54±0.64 4.35±1.00 6
CD19+CD24highCD38high 38 20 1.26±0.45 3.14±0.87
Heinemann K 
et al.
Germa-
ny *ACR
Partial 
treated >4 IL-10+ 34 21 5.50±4.80 17.00±7.00 5
CD19+CD24highCD38high 34 21 1.60±2.60 1.50±1.10
Wang H et al. China 1982 Partial treated >5 CD19+CD24highCD38high 30 30 2.70±1.97 0.38±0.33 5
Vadasz Z et al. Israel 1992 Untreated Not report CD19+CD25high 21 20 18.50±3.05 11.00±1.65 5
Wang T et al. China 1997 Not report Not report CD19+CD24highCD38high 56 35 39.83±21.39 8.74±3.97 5
Yang X et al. China 1997 Treated ≥6 CD19+CD5+CD1dhigh 16 15 4.90±1.27 1.63±0.99 5
IL-10+CD19+ 6 6 3.44±0.69 1.15±0.45
Wang Z et al. China 1997 Untreated ≥5 CD19+CD24highCD38high 28 30 2.10±1.09 4.07±1.48 5
Notes: *ACR without detailed description
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3.3 Meta-Analysis of the Breg Percentages in Ac-
tive SLE Patients and Publication Bias
Initially, we compared the percentages of Bregs in active 
SLE patients and healthy controls, regardless of the Breg 
definitions were used. A total of ten studies were available 
in seven eligible articles, and five studies reported higher 
percentage of Bregs in active SLE patients than those in 
the control group [10-13], three studies reported decreased 
percentages [8,14]. In addition, the simultaneous analysis 
of two different subtypes of Breg in two studies from one 
articles yielded conflicting results [9]. Surprisingly, in the 
overall analysis, there was no significant difference in 
any studies [0.259, (−1.150, 1.668), p = 0.719, Figure 2]. 
Meanwhile, the heterogeneity was 97.5% (p < 0.001) by 
I2 statistic and thus very high, and a random effect model 
was used for meta-analysis. The Egger test showed no 
publication bias (t = 0.13, p = 0.898, Figure 3).
Figure 2. Forest plot of the percentage changes of Bregs 
in active SLE patients compared with the controls. α: 
Bregs were gated by IL-10+CD19+; β: Bregs were gated 
by CD19+CD24highCD38high; γ: Bregs were gated by IL-
10+; δ: Bregs were gated by CD19+CD5+CD1dhigh
Figure 3. Publication bias analysis using Egger linear 
regression and Begg rank correlation test
3.4 Sensitivity Analysis and Subgroup Analysis 
Due to the high heterogeneity of the results, we performed 
a sensitivity analysis. Then, considering the different 
phenotypes of Bregs, diagnostic criteria, enrolled regions, 
threshold of SLEDAI chosen for active SLE definition, 
treatment status, and organ involvement are potential fac-
tors that may lead to bias in the results, we performed a 
subgroup analysis based on these factors.
Firstly, we performed sensitivity analysis to explore 
potential sources of heterogeneity. Exclusion of any single 
study or single article did not materially resolve the het-
erogeneity. But after excluding the article conducted by 
Cai X and his colleagues [8], the percentages of Bregs were 
significantly higher in active SLE than those in controls 
[1.394, (0.114,2.675), p = 0.033].
Then, we hypothesized that the main cause of unex-
pected results may be the inconsistent definition of Bregs. 
Therefore, we performed a subgroup analysis based on the 
Bregs definition to explore potential sources of heteroge-
neity. There are several subtypes in the selected articles, 
which can roughly divide Bregs into two groups: based 
on IL-10+ and CD19+(Table 2). To our surprise, no matter 
whether Breg was based on IL-10+ or CD19+, there was 
no statistical difference between SLE patients and control 
groups. When Bregs were gated based on IL-10+, the per-
centages of Bregs in active SLE were comparable to those 
in the controls [-0.783,(-3.526,1.960), p = 0.576, Figure 4] 
[8,9,13]. Meanwhile, pooled analysis of nine studies revealed 
the proportion of Bregs defined as CD19+ cells did not dif-
fer significantly between active SLE patients and healthy 
controls [0.517,(-0.979,2.014), p = 0.498, Figure 5] [8,10-14].
Table 2. Subgroup analysis based on different definitions 
of Bregs in patients with SLE
Definition of Bregs
Number of 
studies
Test of association
SMD 95%CI P value
Association with IL-10-posi-
tive 3 -0.783 (-3.526,1.960) 0.576
IL-10+CD19+ 2 0.106 (-7.272,7.484) 0.978
IL-10+ 1 -2.007 (-2.672,-1.342) -
Association with CD19-posi-
tive 9 0.517 (-0.979,2.014) 0.498
IL-10+CD19+ 2 0.106 (-7.272,7.484) 0.978
CD19+CD24highCD38high 5 -0.186 (-1.856,1.483) 0.827
CD19+CD5+CD1dhigh 1 2.86 (1.841,3.879) -
CD19+CD25high 1 3.037 (2.127,3.948) -
From the articles we collected, it was found that the re-
searchers did not agree on the diagnostic criteria for active 
SLE patients. Six of the studies were based on the 1997 
diagnostic criteria [8,12-14], one based on the 1982 ACR 
standard [10], and three studies showing only the ACR cri-
teria without specific years [9,11]. Therefore, we conducted 
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a subgroup analysis to explore whether it is a source of 
heterogeneity. However, our subgroup analysis showed no 
statistically significant difference between the percentages 
of Bregs calculated using the 1997 diagnostic criteria and 
the ACR diagnosis criteria [0.008,(-2.203,2.219), p = 0.994 
for subgroup of 1997, 0.340,(-2.137,2.817), p = 0.788 for 
subgroup of ACR, Figure 6].
More and more recent studies have shown that SLE has 
geographical and ethnic differences [16], so we assumed 
that the heterogeneity was caused by the different coun-
tries of the research population. There are differences in 
the prevalence and incidence of SLE in different coun-
tries, which may have a certain impact on the percentages 
of Bregs. Of the ten studies, seven were conducted in 
China [8,10,12-14], two in Germany [9], and one in Israel [11]. 
However, by subgroup analysis, the percentages of Bregs 
in each subgroup of SLE patients and controls was still 
not statistically significant(Figure 7).
Our results revealed that choosing the SLEDAI score 
to distinguish thresholds between active SLE and inac-
tive SLE may result in heterogeneity. We attributed the 
study with a SLEDAI score of >4 to the ≥5 group [9], and 
the study with a score of >5 to the ≥6 group [10]. There-
fore, ultimately all studies could be divided into three 
subgroups, “≥5” group, “≥6”group and “not reported” 
group(Figure 8). When the disease activity was judged 
by SLEDAI score ≥ 5, the percentages of Bregs were 
significantly lower in the SLE groups than in the control 
groups[-1.99,(-3.241,-0.739), p = 0.002] [8,9,14], but when 
the threshold of SLEDAI score ≥ 6 chosen for active SLE, 
the percentages of Bregs were significantly increased in 
the SLE groups[2.546,(1.333,3.759), p ＜ 0.001] [10,13].
Previous study suggested that glucocorticoid therapy can 
increase the frequency of Bregs in patients with SLE [17]. 
The subgroup treatment status analysis of this meta-anal-
ysis showed no statistically significant differences among 
studies receiving drug therapy or those partially receiving 
drugs or no drug therapy(Figure 9). Given the fact that most 
patients who enrolled in the current studies received med-
ication and the differences in the use of drugs, the possible 
effects of the treatment require further evaluation.
SLE can involve many organs, and lupus nephritis (LN) 
is a typical major organ involving of SLE. In all articles, 
Heinemann K et al. [9] compared the percentages of two 
different Breg subtypes in LN with the healthy control 
group. The data showed that the percentages of Bregs in 
active LN was not statistically different from the healthy 
controls[-1.010,(-2.882, 0.863), p ＜ 0.291].
To assess the impact of disease activity further, we an-
alyzed the percentages of Breg in active SLE versus in in-
active SLE and in inactive SLE versus in healthy controls. 
The results presented are also not statistically significant. 
Figure 4. Subgroup analysis based on IL-10+ as definition 
of Bregs in SLE patients
Figure 5. Subgroup analysis based on CD19+ as definition 
of Bregs in SLE patients
Figure 6. Subgroup analysis based on different diagnose 
criterion in SLE patients
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Figure 7. Subgroup analysis based on different study 
regions in SLE patients
Figure 8. Subgroup analysis based on different thresh-
olds of SELDAI chosen for active SLE definition in SLE 
patients
Figure 9. Subgroup analysis based on different treatment 
status in SLE patients
4. Discussion
B cells are one of the main components of specific im-
munity, and play a positive regulatory role mainly by 
initiating and activating immunity. Including secretion of 
antibodies, antigen presentation, production of inflamma-
tion and immunoregulatory factors, providing synergistic 
stimulation signals, etc. It is known that T cells have im-
munoregulatory functions, and whether B cells have reg-
ulatory subpopulations has become a research hotspot in 
recent years. Increased or decreased percentage of Bregs 
has been reported in patients with active SLE [8-14]. There-
fore, we conducted further research on these results. How-
ever, meta-analysis results found no significant difference 
in percentages of Bregs between active SLE patients and 
healthy controls. Since the results showed great heteroge-
neity (I2> 90), sensitivity analysis and subgroup analysis 
was subsequently performed to evaluate the possible ef-
fect of several factors on the percentages of Bregs, and the 
results indicated that different thresholds of SLEDAI cho-
sen for defining active SLE might influence the frequency.
When studying Bregs, it is important to determine 
their phenotype. Previous research found that Bregs can 
produce IL-10, TGF-β, and Foxp3. One subtype of Bregs 
mainly secrete IL-10, which can inhibit the differentiation 
of T helper cells 1 (Th1) and T helper cells 17 (Th17) 
, and reduce the production of inflammatory cytokines 
through dendritic cells [18]. Such IL-10-producing Bregs 
are called B10 cells. In humans, B10 cells account for 
less than 1% of the total number of B cells in the blood. 
Human Bregs include CD19+CD24highCD38highCD1dhigh 
and CD19+CD24highCD27+, etc [19]. The relationship be-
tween development and differentiation of these subtypes 
of Bregs is unclear. In addition, Breg functioning involves 
CD40, TLR, B cell receptor, CD19, CD1d, etc [20]. In this 
study, no statistically significant difference was found in 
the different statistical strategies of Bregs subtype clas-
sification. Normal frequencies were observed when IL-
10+ was chosen to define Bregs [-0.783, (-3.526,1.960), p 
= 0.576] [8,9,13]. The percentages of Breg based on CD19+ 
did not show a significant difference between the patients 
and the control group [0.517 , (-0.979, 2.014), p = 0.498] 
[8,10-14]. Considering that some studies only mentioned IL-
10+ Bregs, but did not mention the specific Bregs subtypes 
that secreted IL-10, and the research sample size was 
insufficient, further researches on the frequency of Bregs 
with different subtypes are needed in the future.
Since SLE is a heterogeneous disease, the diagnosis is 
not always so simple. From American College of Rheuma-
tology (ARA) established the SLE classification standard 
in 1971 [21], many changes have taken place in the diag-
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nostic criteria for SLE. The effect of different diagnostic 
criterion on the percentages of Bregs was not found in our 
study, and the results showed no statistical significance. 
However, the underlying causes and mechanisms leading 
to this result need to be further clarified in the future.
Recently, many studies have shown that there are 
significant regional differences in the incidence, clinical 
manifestations, and mortality of SLE. Khan A et al. [22] 
showed that significant regional differences existed in the 
clinical manifestations of SLE in Khyber Pakhtunkhwa 
compared to other regions through cross-sectional studies. 
In addition, Yen EY et al. [23] found that the United States 
since 1968, mortality of SLE has declined, but it remains 
higher than mortality in non-SLE, and there were signif-
icant gender, ethnic, and regional differences. Therefore, 
we hypothesized that differences in the study regions 
may result in variability in the results, but unexpectedly, 
the analysis results showed that the percentages of Breg 
in SLE patients from different regions was comparable 
to these of the healthy control group. We considered that 
most of researches originated in China, while the sample 
size of other countries was small, China had a large land 
area, a large span of latitudes and longitudes, different 
environments and ethnicities, which would also cause het-
erogeneity of Bregs in SLE patients. Thus, a larger sample 
size studies are needed for analysis.
The SLEDAI score can be used to judge the condition 
of SLE. Different scores indicate differences in disease 
activity, which determine the use of different doses of glu-
cocorticoid and the choice of different immunosuppres-
sants [24]. Our results revealed that active SLE could cause 
heterogeneity by choosing different thresholds of SLE-
DAI score. When SLEDAI score ≥ 5 was defined as active 
SLE, the percentages of Bregs in patients with active SLE 
were significantly lower than those in the healthy control 
group [-1.99, (-3.241-0.739), p = 0.02] [8,9,14]; however, 
the percentages of Bregs in patients with active SLE were 
significantly higher than control groups, when SLEDAI 
score ≥ 6 as the activity standard [2.546, (1.333, 3.759), p 
<0.001] [10,13]. Considering that higher thresholds of SLE-
DAI score in recruited SLE patients may indicate a more 
severe conditions, Bregs seems to be positively correlated 
with disease activity in SLE, but this does not explain that 
the percentages of Bregs in SLE patients with a slightly 
lower SLEDAI score were lower than in healthy controls. 
Therefore, the changes of Bregs in the process of SLE dis-
ease need to be further studied.
Drug treatment for patients with SLE includes glucocor-
ticoid, hydroxychloroquine, cyclophosphamide, and aza-
thioprine etc. Previous studies showed that glucocorticoid 
therapy can increase the frequency of Bregs in patients with 
SLE [17]. However, the use of cyclophosphamide appeared 
to reduce the amount of Bregs [25]. Results of the subgroup 
analysis based on treatment status did not reveal a statisti-
cal difference between patients who received drug therapy 
and untreated patients. Drugs for SLE are diverse, and 
each SLE patient enrolled in the studies received different 
treatment status and used different drugs. Thus the possible 
effects of different treatment modalities on Bregs need to be 
further evaluated in the future.
Recently, studies by Szabó K et al. and Makiyama A. 
et al. found that activated T helper cells, especially Th1 
cells, were associated with the promotion of B cell dif-
ferentiation in SLE patients [26-27]. On the one hand, Bregs 
can secrete IL-10, TGF-β and other related factors, inhibit 
the conversion of Th0 to Th1 and Th2, reduce the produc-
tion of inflammatory factors such as TNF-α and IFN-γ, 
and down-regulate autoimmune response and excessive 
immunity [28-29]; On the other hand, Bregs can exert immu-
noregulatory effects by affecting the number and function 
of Tregs [30]; Bregs can also suppress the immune response 
through cell-to-cell contact, such as by contacting CD40 
/ CD40L with effector T cells and causing T cells death 
[31]. It seems that the Bregs and T cells can interact and 
influence each other. In the past, Zhang SX et al. [32] sys-
tematically reviewed and performed a meta-analysis about 
the proportion of Tregs in patients with SLE, the results 
showed that the percentages of Tregs in SLE patients was 
significantly lower than those in healthy controls. Consid-
ering the correlation between Bregs and Tregs, we evalu-
ated the proportion of Bregs in SLE patients, and analyzed 
the relevant influencing factors to obtain more evidence 
about Bregs in the pathogenesis of SLE, which may aid in 
the development of approaches to the therapeutic modali-
ties employing the use of Bregs.
The present study has certain limitations. First of all, 
not all research-related information is publically available, 
such as the duration of the disease, specific information 
on the use of drugs or treatments, etc., and we did not 
contact the corresponding authors in time to obtain more 
information, which prevented us from comprehensive in-
vestigation of the disease course and the effect of drugs on 
the percentages of Bregs. Second, our assessment of the 
factors affecting the percentages of Bregs was inadequate. 
Faced with a high degree of heterogeneity, more SLE pa-
tients who are in different backgrounds and disease status 
need to be studied, which may help to clarify the role and 
changes of Bregs in SLE disease process better.
5. Conclusion
In summary, our meta-analysis results suggest that Bregs 
may play a role in the pathogenesis of active SLE, and the 
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thresholds of SLEDAI score to distinguish whether SLE 
patients are active or not are important factors affecting 
the percentages of Bregs. Our findings support the notion 
that Bregs status is important in patients with SLE, but we 
cannot determine how Bregs have changed throughout the 
course of SLE. Due to the evidence is still limited, more 
and further large-scale and well-designed randomized 
controlled trials are urgently needed.
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